Novel compound blocks replication of Zika and other viruses

May 2, 2017
Transmission electron microscope image of negative-stained, Fortaleza-strain Zika virus (red), isolated from a microcephaly case in Brazil. The virus is associated with cellular membranes in the center. Credit: NIAID

The cells of vertebrates have evolved pathways that act like an internal defense, inhibiting viral infections by preventing replication of the pathogens. Drugs that activate those existing systems suggest a promising novel approach to treating dangerous infections by Zika and other viruses, say researchers from the Vaccine and Gene Therapy Institute at Oregon Health and Science University (OHSU), in Portland.

In a new study published this week in mBio, the scientists report on a novel compound that triggers a cell's innate antiviral system, inhibiting replication of Zika, Chikungunya, and Dengue viruses.

Recent outbreaks of Zika and Chikungunya infections that began in Latin and South America and spread to other continents—as well as the ongoing presence of Dengue—have spurred disease researchers to search for new antiviral medications. No treatments are available for the three infections, and only Dengue has a vaccine, which is licensed in some Asian and South American countries where the disease is endemic.

The three viruses spread by way of the same mosquito species and elicit similar symptoms. Chikungunya emerged in the Americas in Caribbean islands in 2013, and since then it has infected more than a million people on five continents. Zika was first identified 70 years ago, but a 2015 outbreak that began in Brazil has spread to 50 countries and, according to estimates from the World Health Organization, will infect three to four million people this year. Zika during pregnancy can cause severe birth defects, including microcephaly. More than 350 million people are infected with Dengue annually; the virus is a leading cause of illness and death among children in some countries.

Virologist Victor R. DeFilippis, at OHSU, led the work. He predicts that cellular innate immune responses may be pharmacologically harnessed to block infections as a kind of antiviral immunotherapy. "The tools that we need to fight off virus infection are programmed into our cells as a result of evolution," he says. "I think that's a potentially lost opportunity for the identification of novel broad-spectrum antiviral strategies."

Interferons are proteins, secreted by cells, that are known to induce protection against a wide variety of infections, including viral. In the new paper, DeFilippis and his colleagues report on a novel small molecule, which they named AV-C, that triggers the built-in cellular defenses by activating the interferon system. In lab experiments, the researchers treated human fibroblasts with AV-C and, six hours later, infected the cells with one of the three viruses. The drug kept the viral presence low, leading them to conclude that AV-C establishes a cellular state antagonistic to replication. AV-C also triggered secretion of other proinflammatory cytokines, suggesting that it may have potential to enhance vaccine efficacy.

The researchers also investigated whether the molecule has potential therapeutic effects by administering it to cells after infection with Zika and Chikungunya. For Zika, the results were promising. AV-C did block Zika replication in the cells when administered as late as 16 hours post-infection. For Chikungunya, however, the molecule failed to block replication when given just two hours post-infection.

Next, says DeFilippis, the researchers need to evaluate the clinical utility of the drug in animal models. Early experiments in mice suggest AV-C does not inhibit replication in those animals, but DeFilippis hopes to test it in other species, such as nonhuman primates.

He sees AV-C as the first of a family of compounds worth exploring. He and his team found the drug by using high-throughput screening to examine 51,000 different compounds that might trigger the innate response. After they narrowed down their list to a few promising candidates, AV-C was one of the first they studied in earnest.

"There are potential drugs out there we haven't really taken a look at," says DeFilippis. "We're characterizing a number of other agents that are just as promising, and many are even more promising."

Explore further: Immune molecule protects against Zika virus infection in animal models

Related Stories

Immune molecule protects against Zika virus infection in animal models

March 14, 2017
A molecule naturally produced by the immune system protects mice and monkeys against Zika virus infection, an international team of researchers has found. Administering the molecule, called 25-hydroxycholesterol or 25HC, ...

Study demonstrates how Zika virus rewires and repurposes invaded cells

March 30, 2017
New research reveals a high-resolution view of the Zika viral life cycle within infected cells and shows dramatic changes in the cell's architecture throughout the infection process. This novel perspective may lead to the ...

More evidence that Zika mRNA vaccines can stop viral replication in mice

February 17, 2017
Vaccine developers have successfully protected mice against Zika by injecting synthetic messenger RNA that encodes for virus proteins into the animals. The cells of the mice then build parts of the virus, training the immune ...

Study shows prior viral infections can make Zika infection worse

March 31, 2017
(Medical Xpress)—A team of researchers with the Icahn School of Medicine at Mount Sinai in New York City has found that mice who have survived a dengue or West Nile viral infection fare worse when subsequently infected ...

Zika virus blindfolds immune alarm cells

February 2, 2017
Gatekeeper immune cells are fighting Zika virus with an arm tied behind their backs, scientists from Emory Vaccine Center report.

Zika virus protein mapped to speed search for cure

March 27, 2017
A study published today shows how Indiana University scientists are speeding the path to new treatments for the Zika virus, an infectious disease linked to birth defects in infants in South and Central America and the United ...

Recommended for you

Anti-malaria drug shows promise as Zika virus treatment

November 17, 2017
A new collaborative study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC San Diego School of Medicine has found that a medication used to prevent and treat malaria may also be effective ...

Decrease in sunshine, increase in Rickets

November 17, 2017
A University of Toronto student and professor have teamed up to discover that Britain's increasing cloudiness during the summer could be an important reason for the mysterious increase in Rickets among British children over ...

Scientists identify biomarkers that indicate likelihood of survival in infected patients

November 17, 2017
Scientists have identified a set of biomarkers that indicate which patients infected with the Ebola virus are most at risk of dying from the disease.

Research team unlocks secrets of Ebola

November 16, 2017
In a comprehensive and complex molecular study of blood samples from Ebola patients in Sierra Leone, published today (Nov. 16, 2017) in Cell Host and Microbe, a scientific team led by the University of Wisconsin-Madison has ...

Study raises possibility of naturally acquired immunity against Zika virus

November 16, 2017
Birth defects in babies born infected with Zika virus remain a major health concern. Now, scientists suggest the possibility that some women in high-risk Zika regions may already be protected and not know it.

A structural clue to attacking malaria's 'Achilles heel'

November 16, 2017
Researchers from The Scripps Research Institute (TSRI) and PATH's Malaria Vaccine Initiative (MVI) have shed light on how the human immune system recognizes the malaria parasite though investigation of antibodies generated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.